PATENT CLAIM ANALYSIS

Application Number: 15892229
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["548", "253000"]

Abstract:
Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.

Claim (Index 68):
A method of treating an autoimmune disorder comprising the step of administering to a subject in need thereof an effective amount of a compound of formula or a pharmaceutically acceptable salt thereof, wherein\n Ring Hy represents \n optionally substituted with R\u2032\u2033;\n R 1  and R 2  are the same or different and are independently selected from CH 3 , CH 2 F, CHF 2 , CF 3 , substituted or unsubstituted C (3-5) cycloalkyl, CH 2 \u2014OR a , CH 2 \u2014NR a R b , CN and COOH with the proviso that:\n a) both R 1  and R 2  at the same time do not represent CF 3 , \n b) both R 1  and R 2  at the same time do not represent CH 3 , \n c) when R 1  is CF 3  then R 2  is not CH 3 ; and \n d) when R 1  is CH 3  then R 2  is not CF 3 ; \n \n Ring Ar represents: \n L 1  and L 2  together represent \u2014NH\u2014C(\u2550O)\u2014; A is absent; R\u2032\u2033 is selected from hydrogen, hydroxy, cyano, halogen, \u2014OR a , \u2014COOR a , \u2014S(\u2550O) q \u2014R a , \u2014NR a R b , \u2014C(\u2550X)\u2014R a , substituted or unsubstituted C (1-6)  alkyl group, substituted or unsubstituted C (1-6)  alkenyl, substituted or unsubstituted C (1-6)  alkynyl, and substituted or unsubstituted C (3-5) cycloalkyl; each occurrence of X is independently selected from O, S and \u2014NR a ; Cy is selected from monocyclic substituted or unsubstituted cycloalkyl group, monocyclic substituted or unsubstituted aryl; and substituted or unsubstituted pyridyl; each occurrence of R a  and R b  are the same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, \u2014OR c , \u2014S(\u2550O) q \u2014R c , \u2014NR c R d , \u2014C(\u2550Y)\u2014R c , \u2014CR c R d \u2014C(\u2550Y)\u2014R c , \u2014CR c R d \u2014Y\u2014CR c R d \u2014, \u2014C(\u2550Y)\u2014NR c R d \u2014, \u2014NR c R d \u2014C(\u2550Y)\u2014NR c R d \u2014, \u2014S(\u2550O) q \u2014NR c R d \u2014, \u2014NR c R d \u2014S(\u2550O) q \u2014NR c R d \u2014, \u2014NR c R d \u2014NR c R d \u2014, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocylyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroarylalkyl, or when R a  and R b  are directly bound to the same atom, they may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR c  and S; each occurrence of R c  and R d  may be same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclylalkyl, or when two R c  and/or R d  substitutents are directly bound to the same atom, they may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which are the same or different and are selected from O, NH and S; each occurrence of Y is selected from O, S and \u2014NR a ; and each occurrence of q independently represents 0, 1 or 2; wherein the autoimmune disorder is chronic obstructive pulmonary disease, inflammatory bowel disease, allergic rhinitis, multiple sclerosis, psoriasis, Crohn's disease, colitis, ulcerative colitis, arthritis, bone diseases associated with increased bone resorption, or chronic obstructive airway disease.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 88.0
- Lexical Diversity: 1.58974
- Patent Class: 548.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14539470', '12899416', '15635268', '12899410', '14626522']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.820062429705539
- 35 USC 102 Novelty (BERT): 0.6049776434642511
- Combined Prediction Score: 0.7985539510814101
- Mean Citation Score: 511.481862
- Max Citation Score: 550.60614
- Similarity Product: 493.5339901304412

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test